Please upgrade your browser.
Researchers are tackling TACAs in the search for better immunotherapies.
The diagnosis of renal cell cancer in a patient aged 46 or younger should prompt a referral for germline mutation testing and genetic counseling, according to a report published online in the Journal of Clinical Oncology.
Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation
To evaluate the pathological characteristics of peritumoral capsule (PC) and the prognostic effect of capsule penetration on tumor recurrence in patients treated with tumor enucleation for clinically intracapsular renal cell carcinomas (RCCs).
There is a huge volume of research showing the relationship between vitamin D and cancer.
Obese patients with renal cell carcinoma tended to have more indolent tumors than normal-weight patients, according to study results.
Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication.
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for nearly 90 percent of all kidney cancer diagnoses. RCC has several subtypes, which are classified mainly by what the tumor cells look like under a microscope (Table 1). The subtype can both influence treatment choices and help doctors determine whether the cause of the cancer may be an inherited genetic syndrome.
Studies demonstrate the link between smoking marijuana and the increased risk of disease
RX-3117 has broad spectrum anti-tumor activity against 80 different human cancer cell lines (including NSCLC, breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 12 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.
70% of physicians in California are rebelling against the state's Obamacare health insurance exchange and won't participate--these include top-rated kidney cancer doctors.
|Powered by NeonCRM|